251.64
price down icon1.05%   -2.67
after-market After Hours: 250.65 -0.99 -0.39%
loading
Abbvie Inc stock is traded at $251.64, with a volume of 6.87M. It is down -1.05% in the last 24 hours and up +15.58% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$254.31
Open:
$255
24h Volume:
6.87M
Relative Volume:
0.99
Market Cap:
$444.60B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
124.12
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+7.19%
1M Performance:
+15.58%
6M Performance:
+9.53%
1Y Performance:
+35.57%
1-Day Range:
Value
$250.10
$255.50
1-Week Range:
Value
$232.85
$255.99
52-Week Range:
Value
$184.38
$255.99

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
57,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2026-07-31
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Compare ABBV vs LLY, JNJ, MRK, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ABBV icon
ABBV
Abbvie Inc
251.64 447.62B 62.82B 3.60B 19.98B 2.0274
LLY icon
LLY
Lilly Eli Co
1,199.43 1.08T 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
253.97 613.02B 96.36B 21.04B 17.80B 8.6488
MRK icon
MRK
Merck Co Inc
128.50 317.77B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
156.72 296.54B 54.66B 13.58B 16.05B 7.0171

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-30-26 Upgrade BofA Securities Neutral → Buy
Apr-21-26 Initiated Canaccord Genuity Buy
Feb-25-26 Initiated RBC Capital Mkts Outperform
Feb-20-26 Initiated Barclays Overweight
Jan-08-26 Downgrade Wolfe Research Outperform → Peer Perform
Jan-07-26 Resumed UBS Neutral
Dec-10-25 Upgrade HSBC Securities Hold → Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-04-25 Downgrade DZ Bank Buy → Hold
Oct-14-25 Downgrade Erste Group Buy → Hold
Oct-01-25 Downgrade HSBC Securities Buy → Hold
Sep-17-25 Upgrade Berenberg Hold → Buy
Aug-12-25 Resumed Piper Sandler Overweight
Aug-07-25 Upgrade Daiwa Securities Neutral → Outperform
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Neutral
Dec-05-24 Downgrade Daiwa Securities Outperform → Neutral
Nov-22-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-04-24 Upgrade Argus Hold → Buy
Oct-17-24 Initiated Bernstein Mkt Perform
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
07:10 AM

AbbVie (ABBV) Shares Dip After Six-Day Surge Amid $10.9B Acquisi - GuruFocus

07:10 AM
pulisher
04:32 AM

AbbVie shares fell after six-session winning streak - MSN

04:32 AM
pulisher
02:52 AM

Bristol, Merck, AbbVie face House committee probe over China trials - Seeking Alpha

02:52 AM
pulisher
12:34 PM

What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week? - TradingView

12:34 PM
pulisher
12:31 PM

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - Benzinga

12:31 PM
pulisher
12:19 PM

Merck, AbbVie probed by US lawmakers over China clinical trials: report - Yahoo! Finance Canada

12:19 PM
pulisher
10:54 AM

US lawmakers probe Merck and AbbVie China clinical trials - grafa.com

10:54 AM
pulisher
09:19 AM

Why is AbbVie stock slipping today? By Investing.com - Investing.com Canada

09:19 AM
pulisher
09:00 AM

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

09:00 AM
pulisher
08:55 AM

Merck, AbbVie investigated over China military hospital drug trials - Yahoo Finance

08:55 AM
pulisher
06:07 AM

US House committee opens investigation into Merck, AbbVie China drug trials - marketscreener.com

06:07 AM
pulisher
05:58 AM

Nxera reaches fourth R&D milestone under AbbVie accord - The Pharma Letter

05:58 AM
pulisher
04:27 AM

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases - marketscreener.com

04:27 AM
pulisher
02:33 AM

Nxera Pharma Co LtdNxera Pharma To Receive Us$10 Million Milestone Payment From Abbvie Under Collaboration Targeting Neurological Diseases - TradingView

02:33 AM
pulisher
12:26 PM

Big Pharma Has a Case of Merger Mania - The Motley Fool

12:26 PM
pulisher
Jun 29, 2026

AbbVie Climbs to 52-Week High: Is the Pharma Giant Still Worth Buying? - NAI500

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie (ABBV) Reports Positive Results for Epkinly in Lymphoma T - GuruFocus

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie (ABBV) Reports Positive Phase 3 Trial Results for DLBCL T - GuruFocus

Jun 29, 2026
pulisher
Jun 29, 2026

Juvederm Users Say AbbVie Hid Risks Of Filler - Law360

Jun 29, 2026
pulisher
Jun 29, 2026

Is AbbVie (ABBV) One of the 10 Best July Dividend Stocks to Buy? - Insider Monkey

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie lymphoma trial cuts progression risk 60% in Phase 3 test - Stock Titan

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie Stock Rockets 17% With 5-Day Winning Streak - Yahoo Finance

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie (ABBV) Stock After 1-Year 41% Rally And Apogee Deal Valuation Check - Yahoo Finance Singapore

Jun 29, 2026
pulisher
Jun 29, 2026

What's Going On With AbbVie Stock Monday?AbbVie (NYSE:ABBV) - Benzinga

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie (ABBV) Wins Backing For Two RINVOQ Skin Disease Uses In Europe - Yahoo Finance

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy? - Yahoo Finance

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last? - Yahoo Finance

Jun 29, 2026
pulisher
Jun 29, 2026

Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $298 - Moomoo

Jun 29, 2026
pulisher
Jun 29, 2026

$100M AbbVie payment backs REGENXBIO (RGNX) Phase IIb/III eye gene therapy - Stock Titan

Jun 29, 2026
pulisher
Jun 29, 2026

ABBV Gains Traction as CHMP Recommends Upadacitinib for Alopecia Areata - GuruFocus

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie Stock Surges 17%, With A 5-Day Winning Spree - Trefis

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Investing News Network

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Non-segmental Vitiligo - Investing News Network

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie gets positive EU opinion for vitiligo treatment By Investing.com - Investing.com Canada

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie’s upadacitinib receives positive EU opinion for alopecia By Investing.com - Investing.com Canada

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie Inc.(NYSE: ABBV) added to Russell 1000 Value Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Yahoo Finance

Jun 29, 2026
pulisher
Jun 29, 2026

AbbVie’s RINVOQ moves closer to Europe’s first vitiligo pill - Stock Titan

Jun 29, 2026
pulisher
Jun 28, 2026

ABBV Stock Quote Price and Forecast - CNN

Jun 28, 2026
pulisher
Jun 28, 2026

AbbVie stock run lifts pricing on $10.9 billion Apogee deal to six times cost - TechStock²

Jun 28, 2026
pulisher
Jun 28, 2026

AbbVie Inc.(NYSE: ABBV) added to Russell Top 200 Value Benchmark - marketscreener.com

Jun 28, 2026
pulisher
Jun 28, 2026

Skyrizi Just Hit $4.5 Billion in a Single Quarter, AbbVie’s Humira Problem Is Solved - TIKR.com

Jun 28, 2026
pulisher
Jun 27, 2026

AbbVie (ABBV) Wins Health Canada Approval for Boey - Insider Monkey

Jun 27, 2026
pulisher
Jun 27, 2026

AbbVie (NYSE:ABBV) jumps $18 billion Friday, beats Apogee as Skyrizi FDA decision comes Monday - TechStock²

Jun 27, 2026
pulisher
Jun 27, 2026

AbbVie (ABBV) to Acquire Apogee Therapeutics - Insider Monkey

Jun 27, 2026
pulisher
Jun 27, 2026

SCHULHOFF & CO INC's AbbVie Inc(ABBV) Holding History - GuruFocus

Jun 27, 2026
pulisher
Jun 27, 2026

Enterprise value to revenue forward of AbbVie, Inc. CDR (CAD Hedged) – TSX:ABBV - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Key facts: AbbVie Q2 Jul 31; FDA Approves Skyrizi for 6+ & Ped PsA - TradingView

Jun 27, 2026
pulisher
Jun 26, 2026

AbbVie (ABBV) Gains FDA Approval for Skyrizi in Children with Ps - GuruFocus

Jun 26, 2026
pulisher
Jun 26, 2026

ABBV Gains FDA Approval for Skyrizi in Pediatric Psoriasis Treat - GuruFocus

Jun 26, 2026

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
MRK MRK
$128.50
price down icon 0.68%
NVS NVS
$156.72
price down icon 0.55%
AZN AZN
$189.62
price down icon 0.70%
JNJ JNJ
$253.97
price down icon 1.76%
NVO NVO
$47.94
price down icon 0.83%
Cap:     |  Volume (24h):